Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBIT (2022 - 2025)

Gossamer Bio's EBIT history spans 4 years, with the latest figure at -$46.0 million for Q4 2025.

  • For Q4 2025, EBIT fell 27.43% year-over-year to -$46.0 million; the TTM value through Dec 2025 reached -$170.7 million, down 184.93%, while the annual FY2025 figure was -$170.7 million, 184.93% down from the prior year.
  • EBIT reached -$46.0 million in Q4 2025 per GOSS's latest filing, up from -$49.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $52.1 million in Q2 2024 to a low of -$56.0 million in Q3 2022.
  • Average EBIT over 4 years is -$39.6 million, with a median of -$46.2 million recorded in 2023.
  • Peak YoY movement for EBIT: surged 212.5% in 2024, then plummeted 174.42% in 2025.
  • A 4-year view of EBIT shows it stood at -$54.4 million in 2022, then grew by 9.81% to -$49.0 million in 2023, then increased by 26.31% to -$36.1 million in 2024, then dropped by 27.43% to -$46.0 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's EBIT are -$46.0 million (Q4 2025), -$49.1 million (Q3 2025), and -$38.8 million (Q2 2025).